The 40-mg fexuprazan tablet A is bioequivalent to tablet B with comparable AUC and Cmax, both well tolerated without meaningful safety differences.
Is the novel 40-mg fexuprazan formulation bioequivalent to the initially developed formulation in healthy Korean subjects?
A novel 40-mg fexuprazan formulation is bioequivalent and has a comparable safety profile to the original formulation in healthy Korean subjects.
Absolute Event Rate: 0% vs 0%
The novel 40-mg fexuprazan formulation (tablet A) was demonstrated to be bioequivalent to the initially developed formulation (tablet B), with comparable systemic exposure (AUC) and peak concentration (Cmax). Both formulations were well tolerated, with no clinically meaningful differences in adverse event profiles.
Hur et al. (Sun,) reported a other. The 40-mg fexuprazan tablet A is bioequivalent to tablet B with comparable AUC and Cmax, both well tolerated without meaningful safety differences.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: